Benlong Tablets contain Benidipine Hydrochloride 4 mg or 8 mg.

Benlong Tablets contain Benidipine Hydrochloride, a dihydropyridine calcium channel blocker that provides effective control of hypertension and long-term prophylaxis of angina pectoris. Benidipine uniquely blocks L-, N-, and T-type calcium channels, producing sustained vasodilation while reducing aldosterone production through inhibition of T-type calcium channels in the adrenal glands and kidneys. This triple-channel blocking activity contributes to effective blood pressure reduction, improved coronary blood flow, and cardiovascular protection with convenient once-daily dosing for hypertension.

Benlong Tablets are indicated for the treatment of hypertension and the long-term prophylactic management of angina pectoris.

Benidipine is a dihydropyridine-derived calcium channel blocker that inhibits L-type and N-type calcium channels, resulting in relaxation of vascular smooth muscle and vasodilation, thereby reducing peripheral vascular resistance and lowering blood pressure. It also blocks T-type calcium channels in the adrenal glands and kidneys, leading to reduced aldosterone production, which further contributes to blood pressure control and cardiovascular protection.

For the treatment of hypertension, the recommended adult dose is 4 mg orally once daily, which may be increased to 8 mg once daily if required. For the long-term prophylactic management of angina pectoris, the recommended dose is 4 mg orally twice daily, or as directed by the physician.

Benlong Tablets are contraindicated in patients with known hypersensitivity to Benidipine Hydrochloride or any component of the formulation.